BSC SYMPOSIUM
SAVE THE DATE
Our annual symposium will be held on Saturday, December 7, 2024
This year’s symposium will focus on the interaction between lipid as well as management of small vessel disease.
Registration is now open!
BSC statement regarding the use of TNK for treatment of acute ischemic stroke
The Belgian Stroke Council is currently awaiting a decision by FAGG and RIZIV/INAMI regarding marketing and reimbursement of tenecteplase (TNK) for treatment of acute ischemic stroke in Belgium.
Based on the current evidence obtained from randomized, controlled trials comparing TNK with alteplase (tPA), the European Stroke Organisation (ESO) has stated that TNK (dosed at 0.25mg/kg) may be used as an alternative for tPA in eligible patients with acute ischemic stroke. The effectiveness and safety of TNK is comparable to tPA. Acute stroke patients with an occlusion of a large intracranial blood vessel may particularly benefit from TNK.
For more information, we refer to the BSC opinion statement and the ESO guideline on the use of TNK, attached to this post.
BSC opinion statement in dutch
BSC Applauds Initial Step in Stroke Care Structuring but Calls for Uniform Criteria Across Regions
On 23 May 2024, the BSC published a press release applauding the recognition of Belgian S2 centres, but calling for uniform certification criteria across the country. Read it here
Remboursement Xarelto 2,5 mg
We are delighted to announce that neurologists also have been recognised for the reimbursement of Xarelto 2.5mg in coronary artery disease (CAD) and peripheral artery disease PAD), since February 1, 2024.
Furthermore, the duration of acceptance has been changed, since the 3-year limit has been withdrawn.
Please find attached Bayer’s information letter: BE.XAR.VAE_Remboursement CADPAD_FR
2023 Symposium minutes
Symposium is closed…
… but it still time to check the summary, the short presentations the speakers made and to have a look at the pictures of the day !
Actilyse vials with latex plugs that could also contain traces of Gentamycine.
Dear members of the SB,
As part of the strategy to resolve the worldwide shortage of thrombolytic therapy, the BSC has been informed that Boehringer-Ingelheim will temporarily produce Actilyse vials with latex plugs that could also contain traces of Gentamycine. These vials could be encountered in your local hospital from the end of October onward (and will likely be produced for several months).
BI states that boxes containing vials with latex plugs and vials that could contain traces of Gentamycine will be clearly labeled by stickers (see photograph). These vials should never be administered to patients with a latex/rubber sensitivity or sensitivity to Gentamycine.
